<DOC>
	<DOCNO>NCT02183246</DOCNO>
	<brief_summary>Determination efficacy safety porfiromycin versus placebo adjuvant radiotherapy postoperative head neck cancer patient well assessment population pharmacokinetic parameter .</brief_summary>
	<brief_title>Porfiromycin Used Adjuvant Radiation Therapy Postoperative Head Neck Cancer Patients</brief_title>
	<detailed_description />
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Porfiromycin</mesh_term>
	<criteria>Male female postoperative radical neck surgery patient histologically proven Stage III IV ( without distant metastasis ) epidermoid ( squamous cell ) carcinoma head neck limit follow location define American Joint Commission ( AJC ) : lip oral cavity , pharynx , larynx . Postoperative radical patient whose specimen ) microscopic positive tumor cell margin ( &lt; 2mm surgical margin ) b ) extranodal capsular spread ( perineuralvascular embolization ) c ) two positive node Postoperative radical neck patient must receive Radiotherapy ( RT ) . Performance status ≥ 70 Karnofsky Performance Score ( KPS ) screening . Patients ≥ 18 year age Patients must provide write informed consent prior participation trial . Patients must demonstrate educational level degree understanding could communicate effectively investigator . Patients receive prior chemotherapy include mitomycinC porfiromycin . Treatment granulocyte , granulocytemacrophage stimulating factor ( GCSF , GMCSF ) Interleukin11 within 30 day prior start RT . RT within treatment field malignancy within past five year . Patients gross ( visible palpable ) residual disease leave surgery . Patients meet follow clinical laboratory criterion upon screening : 1 . Granulocyte ( neutrophil ) count &lt; 1,500/cubic millimeter ( mm3 ) 2 . Platelets &lt; 75,000/mm3 3 . Prothrombin time ( PT ) partial thromboplastin time ( PTT ) &gt; 1.5 time upper limit normal ( ULN ) second . Women pregnant nursing . Women childbearing potential unwilling utilise medically acceptable method contraception ( oral contraceptive , intrauterine device , diaphragm subdermal implant eg : Norplant® ) . Other malignancy active within past five year ( basal squamous cell carcinoma skin outside plan radiation portal , situ carcinoma cervix ) . The presence one primary tumor presence distant metastasis . The presence lifethreatening illness , severe chronic lung , liver , heart disease would expect fatal within five year , regardless patient 's cancer status . Patients participate clinical trial another investigational drug treatment 30 day prior screen .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>